Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of interleukin-22 in the treatment of fatty liver disease

a technology of interleukin-22 and fatty liver, which is applied in the field of medical use of interleukin22 (il22), can solve the problems of fatty liver, cirrhosis and hepatocellular carcinoma, hepatocyte metabolic dysfunction,

Inactive Publication Date: 2014-12-25
GENERON (SHANGHAI) CORP LTD
View PDF5 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new substance called IL-22 that can reduce the buildup of fat in the liver, decrease the levels of certain proteins in the blood, and decrease the amount of free fatty acids in the liver. This substance has potential to treat various medical conditions related to fat buildup in the liver, such as steatosis and hypertriglyceridemia.

Problems solved by technology

The toxic metabolite due to chronic and excessive alcohol metabolism in hepatocytes would result in hepatocytes metabolic dysfunction, leading to fatty liver.
All the therapeutic methods are not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of interleukin-22 in the treatment of fatty liver disease
  • Use of interleukin-22 in the treatment of fatty liver disease
  • Use of interleukin-22 in the treatment of fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Murine IL-22 Gene Cloning

[0083]Cloning of human IL-22 gene: Human peripheral blood monocytes were stimulated with anti-human CD3 mAb and cultured for 24 h. Total RNA was extracted by ultracentrifugation, and cDNA was synthesized with the dT primers. Human IL-22 gene was amplified by PCR with the sense primer (5′-GCA GAA TCT TCA GAA CAG GTT C-3′) and anti-sense primer (5′-GGC ATC TAA TTG TTA TTT CTA G-3′). The amplified DNA is cloned into E. coli expression vector.

[0084]Cloning of mouse IL-22 gene: C57BL / 6 female mice were injected with LPS (5 mg / kg, sc). The spleen was obtained after 20 hours. Total RNA was extracted and cDNA was synthesized with the dT primers. Mouse IL-22 gene was amplified by PCR with the sense primer (5′-CTC TCA CTT ATC AAC TGT TGA C-3′) and anti-sense primer (5′-GAT GAT GGA CGT TAG CTT CTC AC-3′). The amplified cDNA was cloned into E. coli expression vector pET21(+)

[0085]Both human IL-22 and murine IL-22 were verified by DNA sequencing, as shown in FIG. 1 and F...

example 2

22 and Mouse IL-22 Gene Expression

[0086]E. coli strain BL21(+) was used to express the recombinant protein. The E.coli cells were homogenized under high pressure. IL-22 inclusion bodies were obtained by centrifugation and washed with buffers (Tris-HCl 50 mM, NaCl 100 mM, EDTA 1 mM, DTT 1 mM, and sodium deoxycholate 0.5%) completely. Inclusion bodies were solubilized in 8M urea, 50 mM Mes, 10 mM EDTA, and 0.1 mM DTT, pH 6.5. Inclusion bodies was refolded 4 times for 20 hours in 100 mM Tris-HCl, 2 mM EDTA, 0.5 M L-arginine, 1 mM reduced glutathion, and 0.1 mM oxidized glutathion, pH 8. The mixture was then concentrated and purified using a Superdex75 (Amersham) column chromatography. The protein was eluted with 20 mM Tris-HCl, 50 mM NaCl, pH 7. The purity of IL-22 was determined by SDS-PAGE (>95%) as shown in FIG. 3 and FIG. 4. IL-22 protein aliquot was stored at −80 ° C.

example 3

nt IL-22 Decreases Levels of Serum Transaminase in Obese ob / ob Mice

[0087]The recombinant murine IL-22 obtained in example 2 was injected to obese ob / ob mice (8-12 weeks, 35-50 g) at a dose of 300 μg / kg / d for 14 days. Same amount of vehicle solution (0.1% BSA, PBS) was injected to the mice in control groups. The animals were sacrificed at day 15 and the serum was collected. Levels of serum ALT and AST were determined. The results are shown in FIG. 5.

[0088]The results demonstrate that IL-22 can significantly decrease the levels of serum AST and ALT in addition to the decreased levels of serum triglyceride.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a divisional application of U.S. Ser. No. 12 / 672,274 filed on Feb. 5, 2010, which is a US national phase application of PCT International Application No. PCT / US08 / 71859 filed on Aug. 1, 2008, in which the PCT International Application claims benefit of China Application No. 200710044592.7, filed on Aug. 6, 2007, which is incorporated by reference herein in its entirety.FIELD OF INVENTION[0002]This invention relates to the medical use of Interleukin-22 (IL-22). In particular, the present invention relates to use of IL-22 in preparation of pharmaceutical composition for treatment of fatty liver disease (FLD).BACKGROUND OF INVENTION[0003]Fatty liver is a disease in which excessive amounts of lipids accumulate in the liver cells. Normally lipids account for 3%-4% of the total weight of the liver. If the amount of lipid goes beyond 5%, a fatty liver forms. Lipids may comprise up to 40%-50% of the liver weight in severe fatty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/20
CPCA61K38/20A61P1/16A61P3/06A61P43/00
Inventor HUANG, YU LIANGHUANG, ZHI HUASUN, QI
Owner GENERON (SHANGHAI) CORP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com